NDAORALFOR SUSPENSION1 Generic Approved
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
45/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROGRAF (tacrolimus) is a small-molecule immunosuppressant approved in oral suspension form in 2018 for prevention of organ rejection in transplant recipients. It works by inhibiting T-cell activation and proliferation, making it essential for post-transplant maintenance therapy. The drug is currently in its peak commercial lifecycle stage.
Peak1.8 years to LOE
Peak lifecycle positioning indicates stable market demand with established sales infrastructure; brand teams are focused on market maintenance and indication expansion rather than launch activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
Started May 2026
300 enrolled
Pulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)+2 more
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
Started Mar 2026
92 enrolled
Kidney Transplant RecipientsOld Age
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Started Mar 2026
526 enrolled
Kidney Transplant Rejection
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Started Jan 2026
124 enrolled
LeukemiaMyelodysplasiaChronic Myelomonocytic Leukemia
EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS
Started Nov 2025
33 enrolled
Atopic Dermatitis (AD)
Worked on PROGRAF at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.